Zomedica Corp stock (CA98959U1084): earnings update keeps veterinary diagnostics in focus

Veterinary diagnostics specialist Zomedica Corp has reported its latest quarterly figures and continues to invest in growth, while the penny stock remains volatile on NYSE American. What the numbers show and why the business model stays under scrutiny for US investors.

Veterinary diagnostics company Zomedica Corp has recently reported quarterly earnings and updated investors on its growth strategy in companion animal health, while the low-priced stock continues to show pronounced volatility on the NYSE American exchange, according to data compiled by MarketBeat as of 11/07/2024 and company disclosures the same day.MarketBeat as of 11/07/2024Zomedica investor information as of 11/07/2024

As of: 17.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Zomedica Corp
• Sector/industry: Animal health, veterinary diagnostics
• Headquarters/country: Ann Arbor, Michigan, USA
• Core markets: Companion animal veterinary clinics in North America
• Key revenue drivers: Veterinary diagnostics platforms and related consumables
• Home exchange/listing venue: NYSE American (ticker: ZOM)
• Trading currency: US dollar (USD)

Zomedica Corp: core business model

Zomedica Corp focuses on diagnostic and therapeutic products for companion animals, with an emphasis on technologies that can be used directly in veterinary practices. The company positions itself in the growing pet care market, targeting veterinarians who seek in?clinic testing solutions that can improve workflow and reduce turnaround times for results, according to its corporate profile published on 03/14/2024.Zomedica corporate profile as of 03/14/2024

A core element of the business model is to generate recurring revenue from consumables and services once diagnostic platforms are installed at veterinary clinics. This razor?and?blade approach is widely used in diagnostics and aims to offset the initial placement cost with ongoing margins from test cartridges, reagents and service contracts over the life cycle of each system, according to a company overview released on 03/14/2024.Zomedica company overview as of 03/14/2024

The firm operates in a segment that has attracted significant investor interest in recent years as pet ownership and spending on animal health services have increased in the United States. Zomedica aims to capture part of this structural growth by offering differentiated diagnostics technologies and by expanding its installed base among companion animal veterinarians, as highlighted in management commentary accompanying its 2023 annual report published on 03/14/2024.Zomedica annual report commentary as of 03/14/2024

Main revenue and product drivers for Zomedica Corp

Recent financial disclosures indicate that Zomedica generated quarterly revenue of approximately 7 million USD in results released on 11/07/2024, while reporting a net loss that translated into earnings per share of minus 0.01 USD for the same period, according to MarketBeat’s summary of the earnings release dated 11/07/2024.MarketBeat as of 11/07/2024

MarketBeat also reports that, based on the trailing twelve months up to that publication date, Zomedica recorded a negative return on equity of roughly 12.47 percent and a negative net margin of about 232.88 percent, underscoring that the company remains in an investment and scaling phase rather than a mature profitability stage, according to the same 11/07/2024 overview.MarketBeat earnings overview as of 11/07/2024

The company’s revenue base is driven primarily by sales of diagnostic instruments and associated consumables to veterinary practices. As more instruments are placed, the proportion of revenue from consumables and services can become more important, potentially smoothing revenue seasonality and improving gross margin over time. Management has repeatedly highlighted this shift toward recurring revenue in its quarterly filings and webcasts throughout 2024, according to management remarks summarized in its Q3 and Q4 2024 materials published between 08/08/2024 and 11/07/2024.Zomedica financials as of 11/07/2024

Expansion of the company’s commercial footprint, including additional sales representatives and marketing programs targeting US veterinary clinics, is another important driver. These initiatives are intended to increase awareness of Zomedica’s technology and accelerate adoption, especially in regions of the United States where companion animal spending is higher, as discussed in the company’s 2023 Form 10?K filed on 03/14/2024.Zomedica Form 10?K as of 03/14/2024

Why Zomedica Corp matters for US investors

Zomedica’s focus on veterinary diagnostics and therapeutics places it within the broader US healthcare and pet care ecosystem, a sector that has shown resilient demand across economic cycles. For US investors, the company offers exposure to trends in pet ownership and spending, which have been rising over the past decade, according to industry surveys summarized by major animal health research providers on 07/10/2024.Statista US pet care data as of 07/10/2024

Unlike large diversified animal health groups that combine pharmaceuticals, vaccines and diagnostics, Zomedica operates as a smaller, more focused player. This means its financial results can be more sensitive to individual product launches, commercial execution and capital markets access. Investors who follow small?cap healthcare stocks may watch Zomedica as a potential indicator of sentiment toward early?stage animal health innovators listed in the United States, as evidenced by trading patterns around its earnings dates during 2024 and early 2025, according to NYSE American trading data compiled on 11/08/2024.NYSE American data as of 11/08/2024

The stock’s penny?stock status—trading at a low absolute dollar price—can amplify percentage moves in either direction, especially when daily trading volumes spike around news events. For retail investors in the US, this combination of a specialized business model and high volatility may be a reason to monitor Zomedica’s news flow, regulatory filings and liquidity profile closely, rather than relying solely on headline price moves that may be driven by short?term sentiment, according to observations in 2024 trading recaps published by MarketBeat on 11/09/2024.MarketBeat news recap as of 11/09/2024

Conclusion

Zomedica Corp remains a small but visible participant in the US animal health and veterinary diagnostics market. The latest quarterly results point to continued revenue generation, while profitability metrics such as return on equity and net margin remain negative, highlighting the company’s investment stage. For US investors, the stock offers targeted exposure to the pet care and veterinary services trend, but also reflects the risks typical of lower?priced, small?cap healthcare names, where execution, capital allocation and market sentiment can significantly influence returns over time.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.